other material
confidence high
sentiment positive
materiality 0.85
CervoMed reports neflamapimod 54% risk reduction on CDR-SB at Week 32 in DLB trial
CervoMed Inc.
- At Week 32, neflamapimod showed 54% risk reduction in >=1.5-point CDR-SB worsening vs control (p=0.0037); 64% in ptau181<2.2 patients (p=0.0001).
- Significant reduction in plasma GFAP biomarker: mean change -18.4 pg/mL (p<0.0001) for New Capsules over 32 weeks.
- Plans to initiate Phase 3 trial and meet with FDA in Q4 2025 to align on trial design.
- New Capsules achieved target plasma exposures; Old Capsules did not; similar safety profiles.
- Trial funded by $21.3M NIH/NIA grant; 43 sites across US, UK, Netherlands.